The weekly litigation news digest is live. Subscribe now

Fixed Drug Ratios For Treatment Of Hematopoietic Cancers And Proliferative Disorders - EP2120568

The patent EP2120568 was granted to Celator Pharmaceuticals on Nov 15, 2017. The application was originally filed on Feb 15, 2008 under application number EP08730048A. The patent is currently recorded with a legal status of "Revoked".

EP2120568

CELATOR PHARMACEUTICALS
Application Number
EP08730048A
Filing Date
Feb 15, 2008
Status
Revoked
May 10, 2019
Publication Date
Nov 15, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKAug 15, 2018HGF -
TEVA PHARMACEUTICALSAug 15, 2018TEVA PHARMACEUTICALS -

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2005102359
DESCRIPTIONWO2007076117
INTERNATIONAL-SEARCH-REPORTUS2006057111
INTERNATIONAL-SEARCH-REPORTUS2006165649
INTERNATIONAL-SEARCH-REPORTUS2006165771
INTERNATIONAL-SEARCH-REPORTWO2004093795
SEARCHWO2005102359
SEARCHWO2007076117

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents